Pharmacological interventions for treating dyslipidemia in patients with HIV infection
Referencias
Additional references
Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinology and Metabolism Clinics of North America 2009;38(1):207‐22. [MEDLINE: 19217520]
Adeyemi O, Rezai K, Bahk M, Badri S, Thomas‐Gossain N. Metabolic syndrome in older HIV‐infected patients: data from the CORE50 cohort. AIDS Patient Care and STDS 2008;22(12):941‐5. [MEDLINE: 19072100]
Anuurad E, Semrad A, Berglund L. Human immunodeficiency virus and highly active antiretroviral therapy‐associated metabolic disorders and risk factors for cardiovascular disease. Metabolic Syndrome and Related Disorders 2009;7(5):401‐10. [MEDLINE: 19355810]
Bradbury RA, Samaras K. Antiretroviral therapy and the human immunodeficiency virus‐‐improved survival but at what cost?. Diabetes, Obesity & Metabolism 2008;10(6):441‐50. [MEDLINE: 17825081]
Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV‐infected patients receiving HAART. AIDS 2003;17(6):851‐9. [MEDLINE: 12660532]
Calza L, Manfredi R, Pocaterra D, Chiodo F. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. The Journal of Infection 2008;57(1):16‐32. [MEDLINE: 18358535]
Cahn P, Leite O, Rosales A, Cabello R, Alvarez CA, Seas C, et al. Metabolic profile and cardiovascular risk factors among Latin American HIV‐infected patients receiving HAART. The Brazilian Journal of Infectious Diseases 2010;14(2):158‐66. [MEDLINE: 20563442]
Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, et al. Diagnosis, prediction, and natural course of HIV‐1 protease‐inhibitor‐associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353(9170):2093‐9. [MEDLINE: 10382692]
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non‐invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340(8828):1111‐5. [MEDLINE: 1359209]
Crook M. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment. Annals of Clinical Biochemistry 2007;44(3 Pt):219‐31. [MEDLINE: 17456292]
da Silva EF, Bárbaro G. New options in the treatment of lipid disorders in HIV‐infected patients. The Open AIDS Journal 2009;3:31‐7. [MEDLINE: 19639034]
David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clinical Infectious Diseases 2002;34(1):98‐102. [MEDLINE: 11731952]
Denke MA. A novel therapeutic approach. Journal of Managed Care Pharmacy 2003;9(1 Suppl):13‐6. [MEDLINE: 14613354]
Panel on Antiretroviral Guidelines for Adults, Adolescents. Guidelines for the use of antiretroviral agents in HIV‐1‐infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed (August 2 2010)2009:1‐161.
Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Adult AIDS Clinical Trials Group Cardiovascular Subcommittee, HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)‐infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical Infectious Diseases 2003;37(5):613‐27. [MEDLINE: 12942391]
Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002;16(4):569‐77. [MEDLINE: 11873000]
Flexner C. Drug therapy: HIV‐protease inhibitors. New England Journal of Medicine 1998;338(18):1281‐92. [MEDLINE: 9562584]
Fontas E, van Leth F, Sabin CA, Friis‐Møller N, Rickenbach M, d'Arminio Monforte A, D:A:D Study Group. Lipid profiles in HIV‐infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. The Journal of Infectious Diseases 2004;189(6):1056‐74. [MEDLINE: 14999610]
Friis‐Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El‐Sadr WM, Reiss P, Data Collection on Adverse Events of Anti‐HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine 2003;349(21):1993‐2003. [MEDLINE: 14627784]
Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV‐infected subjects on antiretroviral therapy: results of ACTG A5186. Journal of Acquired Immune Deficiency Syndromes 2008;47(4):459‐66. [MEDLINE: 17971707]
Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97(10):946‐52. [MEDLINE: 9529261]
Gurusamy KS, Gluud C, Nikolova D, Davidson BR. Assessment of risk of bias in randomized clinical trials in surgery. The British Journal of Surgery 2009;96(4):342‐9. [MEDLINE: 19283747]
Guyatt G, Oxman AD, Kunz R, Vist GE, Falck‐Ytter Y, Schunemann HJ. What is "quality of evidence"and why is it important to clinicians. BMJ 2008;336(7651):995‐8. [MEDLINE: 18456631]
Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351(9112):1328. [MEDLINE: 9643798]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: 12958120]
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. [updated September 2008]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org2009.
Ioannidis JP. Why most discovered true associations are inflated. Epidemiology 2008;9(5):640‐8. [MEDLINE: 18633328]
Ioannidis JP. Perfect study, poor evidence: interpretation of biases preceding study design. Seminars in Hematology 2008;45(3):160‐6. [MEDLINE: 18582622]
Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV‐infected patients. Journal of Acquired Immune Deficiency Syndromes 2008;49(Suppl 2):79‐85. [MEDLINE: 18725816]
Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, HIV Outpatient Study (HOPS) Investigators. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clinical Infectious Diseases 2010;51(4):435‐47. [MEDLINE: 20597691]
Lifson AR, Neuhaus J, Arribas JR, van den Berg‐Wolf M, Labriola AM, Read TR, INSIGHT SMART Study Group. Smoking‐related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. American Journal of Public Health 2010;100(10):1896‐903. [MEDLINE: 20724677]
Lundgren JD, Battegay M, Behrens G, De Wit S, Guaraldi G, Katlama C, EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Medicine2008; Vol. 9, issue 2:72‐81. [MEDLINE: 18257770]
Lundgren JD, Neuhaus J, Babiker A, Cooper D, Duprez D, El‐Sadr W, Strategies for Management of Anti‐Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV‐infected patients. AIDS 2008;22(14):17‐24. [MEDLINE: 18753925]
Manuthu EM, Joshi MD, Lule GN, Karari E. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients. East African Medical Journal 2008;85(1):10‐17. [MEDLINE: 18543521]
Mason RP, Walter MF, Jacob RF. Effects of HMG‐CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004;109(21 Suppl 1):1134‐41. [MEDLINE: 15173061]
Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, et al. Metabolic syndrome in HIV‐infected patients from an urban, midwestern US outpatient population. Clinical Infectious Diseases 2007;44(5):726‐34. [MEDLINE: 17278068]
Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of success. JAMA 2006;296(7):844‐54. [MEDLINE: 16905789]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486‐97. [MEDLINE: 11368702]
Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004;140(10):795‐801. [MEDLINE: 15148066]
Pullinger CR, Aouizerat BE, Gay C, Coggins T, Movsesyan I, Davis H, et al. Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus‐infected adults. Metabolic Syndrome and Related Disorders 2010;8(3):279‐86. [MEDLINE: 20235745]
Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289(22):2978‐82. [MEDLINE: 12799406]
Shankar SS, Dubé MP. Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. Cardiovascular Toxicology 2004;4(3):61‐9. [MEDLINE: 15470273]
Stancu C, Sima A. Statins: mechanism of action and effects. Journal of Cellular and Molecular Medicine 2001;5(4):378‐87. [MEDLINE: 12067471]
Sudano I, Spieker LE, Noll G, Corti R, Weber R, Lüscher TF. Cardiovascular disease in HIV infection. American Heart Journal 2006;151(6):1147‐55. [MEDLINE: 16781213]
Tomazic J, Silic A, Karner P, Vidmar L, Maticic M, Poljak M, et al. Lipodystrophy and metabolic abnormalities in Slovenian HIV‐infected patients. Wiener Klinische Wochenschrift 2004;116(21‐22):755‐9. [MEDLINE: 15628647]
Tungsiripat M, Aberg JA. Dyslipidemia in HIV patients. Cleveland Clinic Journal of Medicine 2005;72(12):1113‐20. [MEDLINE: 16392725]
World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a public health approach. http://www.who.int/hiv/pub/arv/adult2010/en/index.htmlJuly 2010.
Wohl DA, Tien HC, Busby M, Cunningham C, Macintosh B, Napravnik S, et al. Randomized study of the safety and efficacy of fish oil (omega‐3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy‐associated hypertriglyceridemia. Clinical Infectious Diseases 2005;41(10):1498‐1504. [MEDLINE: 16231263]
